NASDAQ:ASNS - Arsanis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.47 -0.81 (-4.20 %)
(As of 05/22/2018 02:34 AM ET)
Previous Close$19.28
Today's Range$17.90 - $19.41
52-Week Range$10.40 - $28.69
Volume18,400 shs
Average Volume32,763 shs
Market Capitalization$275.60 million
P/E Ratio-1.12
Dividend YieldN/A
BetaN/A

About Arsanis (NASDAQ:ASNS)

Arsanis logoArsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive ASNS News and Ratings via Email

Sign-up to receive the latest news and ratings for ASNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ASNS
CUSIPN/A
Phone781-819-5704

Debt

Debt-to-Equity Ratio0.20
Current Ratio7.38
Quick Ratio7.38

Price-To-Earnings

Trailing P/E Ratio-1.12
Forward P/E Ratio-4.04
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book4.31

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees40
Outstanding Shares14,290,000

Arsanis (NASDAQ:ASNS) Frequently Asked Questions

What is Arsanis' stock symbol?

Arsanis trades on the NASDAQ under the ticker symbol "ASNS."

How were Arsanis' earnings last quarter?

Arsanis (NASDAQ:ASNS) announced its quarterly earnings results on Thursday, May, 10th. The company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.30. View Arsanis' Earnings History.

What price target have analysts set for ASNS?

4 Wall Street analysts have issued 1 year price objectives for Arsanis' shares. Their forecasts range from $23.00 to $27.00. On average, they anticipate Arsanis' stock price to reach $25.3333 in the next twelve months. View Analyst Ratings for Arsanis.

Who are some of Arsanis' key competitors?

Who are Arsanis' key executives?

Arsanis' management team includes the folowing people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 54)
  • Dr. Rene Russo Pharm.D, BCPS, Pres, CEO & Director (Age 43)
  • Mr. Michael P. Gray MBA, CPA, CFO & COO (Age 47)
  • Dr. Anthony Christopher Stevens M.D., Chief Medical Officer (Age 59)
  • Dr. Michael J. Ross, Director (Age 69)

When did Arsanis IPO?

(ASNS) raised $50 million in an initial public offering (IPO) on Thursday, November 16th 2017. The company issued 3,100,000 shares at $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO.

When did the company's lock-up period expire?

Arsanis' lock-up period expired on Tuesday, May 15th. Arsanis had issued 4,000,000 shares in its initial public offering on November 16th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Has Arsanis been receiving favorable news coverage?

Media coverage about ASNS stock has been trending somewhat positive on Tuesday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arsanis earned a news sentiment score of 0.11 on Accern's scale. They also assigned headlines about the company an impact score of 46.86 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Arsanis' major shareholders?

Arsanis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (1.73%), BlackRock Inc. (1.23%), First Eagle Investment Management LLC (0.87%), Sphera Funds Management LTD. (0.80%), Northern Trust Corp (0.22%) and Schwab Charles Investment Management Inc. (0.06%). Company insiders that own Arsanis stock include Polaris Venture Management Co and Tillman U Gerngross. View Institutional Ownership Trends for Arsanis.

Which institutional investors are selling Arsanis stock?

ASNS stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD.. View Insider Buying and Selling for Arsanis.

Which institutional investors are buying Arsanis stock?

ASNS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Eagle Investment Management LLC, Northern Trust Corp, JPMorgan Chase & Co., Schwab Charles Investment Management Inc., California State Teachers Retirement System and New York State Common Retirement Fund. Company insiders that have bought Arsanis stock in the last two years include Polaris Venture Management Co and Tillman U Gerngross. View Insider Buying and Selling for Arsanis.

How do I buy shares of Arsanis?

Shares of ASNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arsanis' stock price today?

One share of ASNS stock can currently be purchased for approximately $18.47.

How big of a company is Arsanis?

Arsanis has a market capitalization of $275.60 million. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. Arsanis employs 40 workers across the globe.

How can I contact Arsanis?

Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected]


MarketBeat Community Rating for Arsanis (ASNS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arsanis (NASDAQ:ASNS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Arsanis in the last 12 months. Their average twelve-month price target is $25.3333, suggesting that the stock has a possible upside of 37.16%. The high price target for ASNS is $27.00 and the low price target for ASNS is $23.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.3333$25.3333$25.3333N/A
Price Target Upside: 37.16% upside5.07% upside105.29% upsideN/A

Arsanis (NASDAQ:ASNS) Consensus Price Target History

Price Target History for Arsanis (NASDAQ:ASNS)

Arsanis (NASDAQ:ASNS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018Cantor FitzgeraldSet Price TargetBuy$26.00MediumView Rating Details
12/11/2017CitigroupInitiated CoverageBuy ➝ Buy$27.00HighView Rating Details
12/11/2017CowenInitiated CoverageOutperformHighView Rating Details
12/11/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$23.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Arsanis (NASDAQ:ASNS) Earnings History and Estimates Chart

Earnings by Quarter for Arsanis (NASDAQ:ASNS)

Arsanis (NASDAQ:ASNS) Earnings Estimates

2018 EPS Consensus Estimate: ($2.49)
2019 EPS Consensus Estimate: ($3.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.79)($0.79)($0.79)
Q3 20181($0.85)($0.85)($0.85)
Q4 20181($0.85)($0.85)($0.85)
Q1 20191($0.87)($0.87)($0.87)
Q2 20191($0.91)($0.91)($0.91)
Q3 20191($0.93)($0.93)($0.93)
Q4 20191($0.97)($0.97)($0.97)

Arsanis (NASDAQ ASNS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($1.04)($0.74)ViewN/AView Earnings Details
3/9/2018Q4 2017($0.8550)($1.68)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arsanis (NASDAQ:ASNS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arsanis (NASDAQ ASNS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 50.90%
Institutional Ownership Percentage: 71.60%
Insider Trading History for Arsanis (NASDAQ:ASNS)
Institutional Ownership by Quarter for Arsanis (NASDAQ:ASNS)

Arsanis (NASDAQ ASNS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017Polaris Venture Management Co.Major ShareholderBuy500,000$10.00$5,000,000.00View SEC Filing  
11/20/2017Tillman U GerngrossDirectorBuy200,000$10.00$2,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arsanis (NASDAQ ASNS) News Headlines

Source:
DateHeadline
-$0.79 Earnings Per Share Expected for Arsanis (ASNS) This Quarter-$0.79 Earnings Per Share Expected for Arsanis (ASNS) This Quarter
www.americanbankingnews.com - May 15 at 11:14 PM
Arsanis (ASNS) Downgraded by Zacks Investment ResearchArsanis (ASNS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 15 at 5:24 PM
Q2 2018 EPS Estimates for Arsanis (ASNS) Increased by Piper JaffrayQ2 2018 EPS Estimates for Arsanis (ASNS) Increased by Piper Jaffray
www.americanbankingnews.com - May 14 at 2:48 AM
Arsanis (ASNS) Releases Quarterly  Earnings Results, Beats Expectations By $0.30 EPSArsanis (ASNS) Releases Quarterly Earnings Results, Beats Expectations By $0.30 EPS
www.americanbankingnews.com - May 11 at 12:46 PM
Arsanis (ASNS) Given a $26.00 Price Target by Cantor Fitzgerald AnalystsArsanis (ASNS) Given a $26.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 10 at 5:37 PM
Arsanis (ASNS) Lock-Up Period Set To End  on May 15thArsanis' (ASNS) Lock-Up Period Set To End on May 15th
www.americanbankingnews.com - May 8 at 1:16 AM
Arsanis (ASNS) Receives Average Rating of "Buy" from BrokeragesArsanis (ASNS) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 4 at 3:38 AM
ValuEngine Upgrades Arsanis (ASNS) to HoldValuEngine Upgrades Arsanis (ASNS) to Hold
www.americanbankingnews.com - May 4 at 12:20 AM
Financial Review: Arsanis (ASNS) and Microbot Medical (MBOT)Financial Review: Arsanis (ASNS) and Microbot Medical (MBOT)
www.americanbankingnews.com - April 30 at 1:21 PM
Arsanis (ASNS) Expected to Announce Earnings of -$1.24 Per ShareArsanis (ASNS) Expected to Announce Earnings of -$1.24 Per Share
www.americanbankingnews.com - April 28 at 11:17 AM
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
finance.yahoo.com - April 20 at 4:06 PM
Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious DiseasesArsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - April 17 at 10:21 AM
Reviewing Arsanis (ASNS) and Its RivalsReviewing Arsanis (ASNS) and Its Rivals
www.americanbankingnews.com - April 17 at 9:21 AM
Zacks Investment Research Downgrades Arsanis (ASNS) to HoldZacks Investment Research Downgrades Arsanis (ASNS) to Hold
www.americanbankingnews.com - April 12 at 5:44 PM
Reviewing Arsanis (ASNS) & Its RivalsReviewing Arsanis (ASNS) & Its Rivals
www.americanbankingnews.com - April 11 at 11:21 AM
 Brokerages Anticipate Arsanis (ASNS) to Post -$1.24 EPS Brokerages Anticipate Arsanis (ASNS) to Post -$1.24 EPS
www.americanbankingnews.com - April 11 at 11:16 AM
Zacks Investment Research Upgrades Arsanis (ASNS) to BuyZacks Investment Research Upgrades Arsanis (ASNS) to Buy
www.americanbankingnews.com - April 10 at 8:28 AM
Arsanis (ASNS) Lowered to "Hold" at Zacks Investment ResearchArsanis (ASNS) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 5:46 PM
Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal AntibodiesArsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies
finance.yahoo.com - April 4 at 5:33 PM
Arsanis (ASNS) and The Competition Financial ReviewArsanis (ASNS) and The Competition Financial Review
www.americanbankingnews.com - April 4 at 5:20 PM
Arsanis (ASNS) Upgraded to "Buy" at Zacks Investment ResearchArsanis (ASNS) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 3 at 6:28 PM
Analyzing Arsanis (ASNS) & Its CompetitorsAnalyzing Arsanis (ASNS) & Its Competitors
www.americanbankingnews.com - April 2 at 11:25 PM
Arsanis (ASNS) Upgraded to "Sell" at ValuEngineArsanis (ASNS) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM
Arsanis Inc (ASNS) Expected to Post Earnings of -$1.24 Per ShareArsanis Inc (ASNS) Expected to Post Earnings of -$1.24 Per Share
www.americanbankingnews.com - March 25 at 1:18 PM
Arsanis (ASNS) Lowered to Hold at Zacks Investment ResearchArsanis (ASNS) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 23 at 5:30 PM
Arsanis (ASNS) Upgraded to Buy at Zacks Investment ResearchArsanis (ASNS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 5:48 PM
Arsanis to Present at the Needham & Company 17th Annual Healthcare ConferenceArsanis to Present at the Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 20 at 10:09 AM
Arsanis Inc (ASNS) Receives Consensus Recommendation of "Buy" from BrokeragesArsanis Inc (ASNS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 15 at 7:38 PM
Arsanis (ASNS) Rating Increased to Buy at Zacks Investment ResearchArsanis (ASNS) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 15 at 6:00 PM
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin AntibodiesArsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies
finance.yahoo.com - March 14 at 11:12 AM
 Arsanis Inc (ASNS) Given Consensus Rating of "Strong Buy" by Analysts Arsanis Inc (ASNS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 11 at 5:28 PM
Arsanis (ASNS) Announces Quarterly  Earnings Results, Misses Expectations By $0.82 EPSArsanis (ASNS) Announces Quarterly Earnings Results, Misses Expectations By $0.82 EPS
www.americanbankingnews.com - March 10 at 9:36 AM
Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017
finance.yahoo.com - March 9 at 11:02 AM
Zacks: Analysts Expect Arsanis Inc (ASNS) to Announce -$3.05 EPSZacks: Analysts Expect Arsanis Inc (ASNS) to Announce -$3.05 EPS
www.americanbankingnews.com - March 8 at 1:56 PM
Arsanis to Present at the 38th Annual Cowen and Company Health Care ConferenceArsanis to Present at the 38th Annual Cowen and Company Health Care Conference
finance.yahoo.com - March 5 at 10:28 AM
Zacks: Arsanis Inc (ASNS) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Arsanis Inc (ASNS) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - February 21 at 9:36 PM
Zacks: Analysts Expect Arsanis Inc (ASNS) Will Announce Earnings of -$3.05 Per ShareZacks: Analysts Expect Arsanis Inc (ASNS) Will Announce Earnings of -$3.05 Per Share
www.americanbankingnews.com - February 19 at 1:16 PM
Analysts Offer Predictions for Arsanis Incs FY2017 Earnings (ASNS)Analysts Offer Predictions for Arsanis Inc's FY2017 Earnings (ASNS)
www.americanbankingnews.com - February 19 at 1:08 AM
 Arsanis Inc (ASNS) Receives Consensus Rating of "Strong Buy" from Analysts Arsanis Inc (ASNS) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - February 18 at 7:40 PM
Arsanis (ASNS) Research Coverage Started at Cantor FitzgeraldArsanis (ASNS) Research Coverage Started at Cantor Fitzgerald
www.americanbankingnews.com - February 14 at 7:12 PM
 Arsanis Inc (ASNS) Given Average Rating of "Strong Buy" by Analysts Arsanis Inc (ASNS) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - February 2 at 7:22 PM
What You Must Know About Arsanis Inc’s (NASDAQ:ASNS) ROEWhat You Must Know About Arsanis Inc’s (NASDAQ:ASNS) ROE
finance.yahoo.com - December 29 at 6:16 PM
Arsanis, Inc.s Quiet Period Will Expire  on December 26th (NASDAQ:ASNS)Arsanis, Inc.'s Quiet Period Will Expire on December 26th (NASDAQ:ASNS)
www.americanbankingnews.com - December 19 at 1:14 AM
Arsanis (ASNS) Coverage Initiated by Analysts at Piper Jaffray CompaniesArsanis (ASNS) Coverage Initiated by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - December 11 at 9:26 PM
Arsanis (ASNS) Now Covered by Analysts at CitigroupArsanis (ASNS) Now Covered by Analysts at Citigroup
www.americanbankingnews.com - December 11 at 12:34 PM
Arsanis (ASNS) Earns Outperform Rating from Analysts at CowenArsanis (ASNS) Earns Outperform Rating from Analysts at Cowen
www.americanbankingnews.com - December 11 at 8:22 AM
Arsanis Announces Pricing of Initial Public OfferingArsanis Announces Pricing of Initial Public Offering
globenewswire.com - November 29 at 8:04 AM
Biotech Arsanis prices IPO at $10, below $15 to $17 price rangeBiotech Arsanis prices IPO at $10, below $15 to $17 price range
finance.yahoo.com - November 23 at 8:44 AM
Arsanis Announces Closing of Initial Public OfferingArsanis Announces Closing of Initial Public Offering
finance.yahoo.com - November 23 at 8:44 AM
Tillman U. Gerngross Acquires 200,000 Shares of Arsanis, Inc. (ASNS) StockTillman U. Gerngross Acquires 200,000 Shares of Arsanis, Inc. (ASNS) Stock
www.americanbankingnews.com - November 20 at 7:36 PM

SEC Filings

Arsanis (NASDAQ:ASNS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arsanis (NASDAQ:ASNS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arsanis (NASDAQ ASNS) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.